Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase-I/II trial.

Abstract

A phase-I/II trial was initiated to study the effect of rhGM-CSF in patients with myelodysplastic syndromes who were not eligible for other kinds of therapy, rhGM-CSF was given to 9 patients in doses of 15 micrograms/m2-150 micrograms/m2 as an intravenous 8-h infusion for a cycle of 7 days followed by an interval of 14 days and a second 7-day treatment course. A dose-dependent increase in the leukocyte count was observed in 7 out of 9 patients. No change in reticulocyte numbers was seen and only 1 patient experienced an increase in platelet count. Toxicity mainly consisted of mild local phlebitis at the site of infusion and sternal pain after bolus injection.

• Authors: A Ganser, B Völkers, J Greher, F Walther, D Hoelzer
• Journal: Onkologie (Onkologie) Vol. 11 Issue 1 Pg. 53-5 (Feb 1988) ISSN: 0378-584X [Print] Switzerland
• PMID: 3283627 (Publication Type: Journal Article)

Chemical References

• Colony-Stimulating Factors
• Growth Substances
• Recombinant Proteins
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Aged
• Colony-Stimulating Factors (adverse effects, therapeutic use)
• Drug Evaluation
• Female
• Follow-Up Studies
• Granulocyte-Macrophage Colony-Stimulating Factor
• Growth Substances (adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Myelodysplastic Syndromes (therapy)
• Recombinant Proteins (adverse effects, therapeutic use)